MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06128629 |
|
Recruitment Status :
Recruiting
First Posted : November 13, 2023
Last Update Posted : May 14, 2024
|
Sponsor:
Intellia Therapeutics
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Intellia Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2027 |
| Estimated Study Completion Date : | April 2028 |